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ABBREVIATIONS 
3G Third generation mobile network HI Haemophilus Influenzae  
AHSN Academic Health Science Network ICF Informed Consent Form 
APEX Software used to report laboratory 
results at PHT.  
IT Information Technology 
BMI Body Mass Index IV Intravenous 
BMS Biomedical Scientist MC&S Microscopy, culture and sensitivity 
BP Blood Pressure ml Millilitres 
BTS British Thoracic Society NCFB Non Cystic Fibrosis Bronchiectasis 
CF Cystic Fibrosis NHS                 National Health Service 
COPD Chronic Obstructive Pulmonary 
Disease 
NICE National Institute of Clinical Excellence 
CRIS Community Respiratory Integrated 
Service project 
NVivo10 Qualitative software package for 
systematic data management 
CRF Case Report Form PA Pseudomonas aeruginosa 
EASHN Eastern Academic Science Health 
Network 
PEA Pseudomonas Exotoxin A 
FEV1 Forced expiratory volume in one 
second 
PHT Portsmouth Hospitals Trust 
FVC Full vital capacity PIS Participant Information Sheet 
GINA Global Initiative for Asthma PPI Public patient involvement 
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GP General Practitioner QAH                Queen Alexandra Hospital 
GCP Good Clinical Practice R&D Research & Development 
GLP Good laboratory practice SpO2 Oxygen saturation 
GOLD Global Initiative for Chronic 
Obstructive Lung Disease 
UK United Kingdom 
REC Research Ethics Committee UoP University of Portsmouth 
RMO Research Medical Officer WHO World Health Organisation 
SBRI Small Business Research Initiative   
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INTRODUCTION 
The burden of respiratory disease with Pseudomonas aeruginosa 
There are an estimated 3 million people in the UK with COPD[1]. Bacteria cause acute exacerbations 
that characterize the course of COPD, and these exacerbations are associated with substantial 
morbidity and mortality.  In addition, bacteria are present in the lower airways of many adults with 
COPD, even during clinically stable periods, contributing to the airway inflammation that is a 
hallmark of COPD.  
The observation that Pseudomonas aeruginosa (PA) is isolated from sputum samples from 4%–15% 
of adults with COPD in many cross-sectional studies[2-4] suggests that the bacterium is a relatively 
common cause of infection in this clinical context. PA is more likely to be isolated from patients with 
severe disease[4], particularly among patients who require mechanical ventilation for severe 
exacerbations.  
PA may cause chronic infections in patients with COPD that are similar to those seen in patients with 
cystic fibrosis (CF). Strains of PA that persist in the airways of adults with COPD demonstrate changes 
characteristic of chronic infection that are similar to changes observed in CF, supporting the 
conclusion that chronic PA infection occurs in the context of COPD.  
The incidence of bronchiectasis in the UK is not certain. Chest x-ray reviews in the 1950s suggested 
an incidence of 100/100,000 with an increase in prevalence with age[5]. With the advent of 
advanced imaging techniques up to 30% of patients with COPD and severe asthma are found to have 
features of bronchiectasis on CT.  
Within our centre, exacerbations of COPD and bronchiectasis are managed through a combination of 
admission to a dedicated 76-bed unit and through self-management by the patient/carer at home. 
Patients are provided educational literature, a care plan and supplies of antibiotics and steroids for 
use at home. Patients are encouraged to recognise signs of exacerbation and to begin immediate 
treatment with antibiotics. They are requested to report when they have initiated antimicrobial 
therapy at home so that this can be followed-up within 2 days (but often do not report because they 
feel better). Best practise recommends that patients are followed-up within 3 weeks after being 
admitted for exacerbation[1]. 
The PHT Respiratory Centre has created a culture of empowering patients through education and by 
transferring the skills required for self-management, so as to reduce rates of admission[6]. The costs 
of providing skilled community staff for home visits has proved uneconomic but the cost burden of 
unscheduled admissions is equally high, necessitating innovative solutions to assist patients to self-
manage. 
Aseptika Ltd (Cambridgeshire, UK) has developed a system for patients to self-monitor important 
physiological measurements including levels of physical activity, peak flow, FEV1 and 1-3 biomarkers 
for PA in sputum.  In a clinical trial sponsored by Papworth Hospital during 2013, data were collected 
by 15 CF participants and uploaded electronically to Activ8rlives– a web-based data collection and 
viewing system developed by the Company.  The study indicated that clinical parameters and sputum 
biomarker changes are likely to enable early detection of exacerbations in CF patients and have a role 
in highlighting treatment failure[7]. The SENSOR study aims to investigate if these tools can be more 
widely applied to other respiratory conditions such as COPD and non-CF Bronchiectasis (NCFB). The 
system includes a sputum assay for bacterial load of PA, physical activity tracker, smart scales, pulse 
oximeter, peak flow meter and self-assessment score system; these all link via a simple iPad interface 
directly to the internet. The differing demographics between this study population and the Papworth 
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population, i.e. the older age of the Portsmouth population, will enable us to learn whether older 
patients with long-term conditions can be trained to use these monitoring devices. 
 
Rationale for study and potential impact 
As described above, initial trials with the Aseptika Ltd.’s system with Cystic Fibrosis patients indicate 
a potential role of this technology in improving patient monitoring and self-management. This is 
particularly important in patients with chronic respiratory conditions for whom the staff to patient 
ratio is typically much lower than CF, and for whom innovative solutions to better enable patients to 
monitor and self-manage their own condition are key to keeping their illness under control.  
It is hoped that the results of this study will enable the self-care planning process that currently exist 
at PHT to be supported with the Aseptika technology to extend the effectiveness of our Home 
Hospital concept. Qualitative feedback from patients and carers will contribute to the continuing 
improvement and adaptation of the system. 
The eventual addition of the Activ8rlives self-monitoring solution (including tests for sputum PA 
load), as an “assist” for the patient and clinical staff, and the provision of an IT infrastructure for staff 
which could simultaneously monitor and mentor many thousand patients with respiratory conditions 
in the Portsmouth area without the costs incurred through undertaking face-to-face home visits 
would have a significant impact both on patient health and NHS costs. The development of this 
infrastructure and subsequent assessment of the effectiveness and cost-effectiveness of the system 
would be assessed in a further large-scale randomised controlled trial. 
 
AIMS AND OBJECTIVES 
Primary Objective 
 To use longitudinal PA sputum biomarker, telemetry and symptom data to develop 
individualisable models to predict a PA exacerbation in chronic non-CF respiratory disease. 
 
Secondary Objectives 
 To investigate the correlation between PA biomarkers and telemetry with clinical outcomes 
during and after treatment of an exacerbation with antibiotics.  
 To describe rates of adherence to data input by participants/carers. 
 To explore whether the self-management platform provided for data upload is feasible and 
acceptable for daily use in this clinical population. 
 To pilot questionnaires to collect data collection on health care utilisation to describe current 
health care usage in this population 
Exploratory Objectives 
 To collect urine samples for future studies which may explore whether biomarkers present in 
urine can also contribute additional information to the exacerbation prediction model.  
 To perform molecular analysis for the HI group to corroborate PA test signals. 
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METHOD 
A mixed methods study: 
A longitudinal cohort of participants and their carers (where appropriate) will be asked to collect 
physiological, biological and disease outcome data over a 6-month period. Neither participants nor 
the clinicians responsible for participants care will have access to the longitudinal data and this 
information will not be used to make clinical decisions. The laboratory samples will be analysed in a 
blinded manner. These data will then be analysed to develop a model for predicting onset of 
exacerbations that can be built into a self-monitoring system. 
Qualitative methods will be used to explore participant and carer experiences of using the 
technology and performing daily self-monitoring assessments. The expected duration of participant 
participation in the cohort will be six months, with an invitation to complete a self-administered 
questionnaire at baseline to inform a face-to-face semi-structured interview with patients with or 
without carer joint participant at the end of the follow-up period (six months completion). 
 
Primary and Secondary Endpoints/Outcome Measures 
Primary endpoint 
An exacerbation will be defined as the initiation of antimicrobial therapy for respiratory symptoms 
either at home or on admission, with or without concomitant steroids or admission. For participants 
who are already on continuous antibiotics, an exacerbation will be defined as starting a course of 
different antibiotics due to increased symptoms, or an increase or dose or frequency.  
Secondary endpoints 
Treatment efficacy will be defined as the day at which antibiotic treatment for that episode is 
completed. 
 
STUDY PARTICIPANTS 
Inclusion Criteria 
The participant must meet ALL of the following criteria to be considered eligible for the study: 
 Male or Female, aged 18 years or above. 
 Diagnosed with at least one (or a combination) of COPD and non-CF bronchiectasis. 
 Two or more exacerbations with the same pathogen (PA or HI) proven on culture, treated 
with antibiotics within the last 12 months, one of which must have been within the last 6 
months. 
 Exacerbation free for the previous 4 weeks. 
 Producing at least 1ml of sputum daily. 
 Must be capable of operating the self-monitoring devices and tablet-based IT system, or 
have a carer capable of undertaking the measurements and collection, storage and transport 
of samples. 
 Participant is willing and able to give informed consent for participation in the study. 
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Exclusion Criteria 
The participant may not enter the study if ANY of the following apply: 
 A suspected or confirmed diagnosis of Cystic Fibrosis 
 Any condition likely to limit participant survival or adherence during the study period in the 
judgement of the clinician, for example malignancy, cirrhosis of the liver.  
 Currently taking part in any other research study. 
Carers who will also be included in the qualitative interview and to aid participants with data upload. 
A carer in this study is defined as an adult (≥18yrs) relative or friend who has frequent contact with 
the participant and will assist the participant to perform measurements or use the iPad mini to 
upload data. 
 
SAMPLING AND SAMPLE SIZE 
 
Using the sputum biomarker(s) to predict exacerbations, the sample size was based on showing a 
difference in exacerbation frequency in time periods when an exacerbation was predicted compared 
to time periods when no exacerbation was predicted. This will give an Odds Ratio of exacerbation 
following detection of sputum biomarkers. 
Time periods will consist of approximately 10 days; of which it will be estimated that there may be 
on average 12 per participant (assuming an average of 4-months of follow-up). It is estimated that an 
exacerbation will occur in 60% of time periods in which it is predicted, and 10% of time periods in 
which it is not predicted. It is also assumed that a predicted exacerbation will be made in only 1 in 12 
time points (8% of all time points). Using a 5% significance level and 90% power it is calculated a total 
of 120 time periods will be required. 
However, as there are multiple time periods from the same participant, the data values are unlikely 
to be independent of each other, and thus the sample size requires inflating. Assuming intra-class 
correlation of 0.18, a design effect of approximately 3 is calculated. This implies that 360 time 
periods are required for the analysis. This equates to a total of 30 participants for the study. 
The proposed 30 participants will consist of: 
- 20 participants with chronic PA infection: 
 10 with primarily COPD 
 10 with non-CF bronchiectasis 
- 10 participants with Haemophilus infection. 
 
STUDY PROCEDURES 
Recruitment 
Potentially eligible patients, identified from clinical databases, will be contacted by a member of the 
research team and invited to attend an information event or specialist research recruitment clinic. 
The information event will be held locally on a Saturday or in the evening to make the event more 
convenient for patients and their carers. The event will allow patients to meet the research team, 
have an educational talk and find out about the study. They will also be able to look at the devices 
and iPad app as well as ask any questions. Patients interested in participating in the study will be 
given a patient information sheet (PIS) and invited to come to a research clinic for screening and 
enrolment. 
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At the research clinic patients will be reviewed by a clinical research fellow and screened for 
suitability for the study by the research team. Patients and carers will be able to view and try out the 
self-monitoring devices and tablet-based IT system. Capacity to operate these systems will be 
assessed as part of screening using a checklist, assessing the patient/carer confidence in using the 
devices and ability to perform the measurements. Those who meet eligibility criteria will be given a 
Participant Information Sheet (PIS) and a Carer Information Sheet (CIS) if necessary.  
After adequate time to read, understand and ask questions (at least 24 hours) patients will be invited 
back to the research clinic to give informed consent. 
Baseline data will be captured on paper CRF’s and uploaded to a local study database, separate to 
the self-monitoring database held by Aseptika Ltd.  
 
Participant/Carer training 
Volunteers will be trained by a Research Nurse and Aseptika personnel during a visit to the 
participant’s home. A home visit will clarify which 3G cellular network is available in their location 
(for internet access) and will ensure that the participant has space to install a small dedicated freezer 
and that there is access for delivery.  
Each participant will be provided with the following items, and training for the participant/carer 
provided on their use: 
 Physical Activity Tracker.  This will be set-up for them and they will be shown how and 
when to wear it. 
 Smart scales.  The participant will be instructed how to weigh themselves and how this 
measures their body composition.  They will be instructed to perform this in bare feet. 
 Blood Pressure.  The participant will be instructed how to take their own blood pressure 
and what the results mean. 
 Pulse oximeter.  The use of a pulse oximeter and how it works will be explained.   
 Temperature.  The participant will be provided with a non-contact infrared thermometer 
and will be shown how to take their temperature. 
 Participants will be shown how to measure their Peak Flow and FEV1 using a simple, 
automated device.  This instruction will be undertaken by the research nurse. 
 Sputum and urine sample.  The participant will be taught how and when to take a sample 
and how to store the sample in the containers provided in the freezer that will be supplied.  
 iPad mini and questionnaire. The participant will be trained on how to charge the iPad mini, 
how to switch it on and off etc. A short questionnaire about symptoms, medications and 
health-care usage will be completed on the iPad mini using a colourful self-explanatory 
series of screens.  The display will be brightly coloured and any text (which will be kept to a 
minimum) will be large in size. 
Participants will be able to use the iPad mini for personal use as well as for daily study use, within the 
limits specified and agreed to in the participant consent form (point 5). Participants will be requested 
to take this equipment with them to hospital if they are admitted and to continue recording these 
data in hospital. Initial training will take approximately 60 minutes.   
Following training, questions about use of the equipment will be handled by the research nurse and 
referred to the Company in the event of technical difficulties with the IT system.  The iPads will be 
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supplied pre-configured with all software installed and an account for the volunteer already created 
and defined.  A remote access technical support solution will also be pre-installed allowing the 
company to remotely access the iPad to resolve problems in the event of significant failures.  If 
required, follow-up visits to the participants will be undertaken.  Every effort will be made to ensure 
that the volunteer is adequately trained and supported for the duration of the study. 
 
Study Assessments 
Participants will be asked to undertake the following once a day every day during a 6 month follow-
up period, with assistance from carers as appropriate. The following picture illustrates the 
equipment that will be provided to the participant to facilitate these assessments. 
 
 
Each participant will be provided with a 3G enabled tablet (iPad) and will upload peak flow, FEV1, 
pulse rate, oxygen saturation, blood pressure, temperature and physical activity data on a daily basis. 
The participants will be provided with a set of instructions about uploading the data onto the iPad. 
The participants will be blind to their continuous data over the duration of the study but will see the 
values generated daily on the screens of the devices. 
There will be no requirement for the participant to enter numerical values into the software.  The 
data collected on the iPad is automatically transmitted to the Cloud databases. No information is 
stored on the iPad and if the iPad is lost, there is no risk that these data could be made available.  
The Company is able to track the iPad’s location in the event that it is stolen or lost. 
The information uploaded by the volunteers will be reviewed daily and remotely to ensure that data 
has been uploaded on a daily basis and there are no technical problems.  Aseptika’s Directors will 
undertake this.  In the event of technical problems, most will be remedied remotely by the Aseptika 
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technical staff.  In the case of information not being uploaded, Aseptika’s investigator will initially 
inform the research nurse who will contact the volunteer by telephone to enquire if there have been 
any difficulties. 
Should any volunteers find the technology difficult to manage, they will be offered a further home 
visit for instructions and training. 
 
Sample production and home storage for sputum and urine samples 
 
 Containers will be pre-labelled with the participant study number, expected contents 
(sputum / urine) and the day and date. 
 Participants will be asked to fill the supplied pot with sputum and ensure the lid is correctly 
sealed. 
 Participants will be asked to collect urine in the bulk container and secure the lid 
 They will then use the Vacutainer and connect it to the cap of the urine container (as per 
supplied instructions) – the Vacutainer will begin to fill with urine. 
 Bulk urine collection pot is to be discarded. 
 Store both containers in sputum and urine collection bags inside of the supplied minus 20°C 
freezer. 
 After 1 month, these will be transferred for bulk storage at the QAH hospital in a designated 
-70°C freezer and a new batch of containers will be provided. 
 
Clinic visits 
Participants will be requested to attend the clinic for a follow-up visit at months 3 and 6 (study 
completion) +/- 2 weeks. 
Participants will attend their normal review with the medical team that usually involves lung 
function, sputum sample for culture and clinical review. They will then have a research visit which 
will involve disease specific control and quality of life questionnaires (QOL-B, SF-36, SGRQ, EQ5D) as 
well as noting any changes to treatment and exacerbations.  
The data collected from these visits will be recorded on paper CRFs which will then be uploaded by a 
member of the research team to a local study database with restricted access. 
Health economics 
In preparation for a future cost-effectiveness trial of the self-management system, a questionnaire to 
collect health care utilisation data will be piloted to capture resource use. These data will be 
analysed descriptively. 
The daily questionnaire on the iPad will ask if participants have been in contact with a health 
professional or been in hospital for the last 24 hours. If they answer yes, they will be prompted to 
give more information about who they saw and for what reason. This will capture data on the 
participants’ health care utilisation for their respiratory condition as well as other conditions. 
 
Qualitative methods 
Qualitative methodology will be used in order to explore the psycho-social questions:  How do the 
participant and main carer experience self-managing their condition under routine care; what is the 
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participant’s expectation of taking part in the study and how do they experience collecting daily self-
monitoring data and using the devices provided? Qualitative research [8,9] seeks to describe, 
understand and explain a particular phenomenon to make explicit the experiences and perceptions 
of the research subjects. This is achieved by exploring the data (usually words) for conceptual 
definitions on how people perceive situations to provide explanations of why something happens in 
a particular way as well as looking for typologies or classifications of grouping of people (or 
situations) that tend to have common characteristics, opinions and experience. Qualitative data will 
be collected at the end of the study (six months) through face to face semi-structured interviews 
with participants, or paired interviews with carers, based on participant preference.  Carers will not 
be interviewed separately.  
All interviews will be guided by a semi-structured topic guide although free discussion of experiences 
and ideas will also be encouraged. The semi-structured interviews will be audio taped and field notes 
taken to describe context, interview process and initial theme development. A choice of venue, 
either at home or suitable hospital room, will be used.  All qualitative interviews will be conducted by 
the same trained research fellow supported and supervised by another experienced qualitative 
researcher. 
It is anticipated that the semi-structured face to face interviews will take between 45 minutes to one 
hour to complete, depending on what the participant wishes to share.  The interview will be 
terminated at any point the participant wishes to stop and this will not influence their subsequent 
treatment. As a small token of appreciation for time given to take part in the interviews, each 
participant will be offered a £10 gift voucher on completion. 
The interviews will be digitally recorded, transcribed verbatim and entered into NVivo 10, a 
qualitative software package for systematic and transparent data management.  All participants’ 
names will be removed from the transcripts to retain confidentiality. Care will be taken to always 
ensure any direct quotes used in study reports or papers to illustrate the findings will not be directly 
attributable to individuals.  
Self-administered questionnaire 
After consent, and on entry to the main study, all patients, but not carers, will be asked to complete 
a self-administered questionnaire (to be developed with advice from the PPI team members) with 
open and closed questions regarding self-awareness/perception of burden of disease, self-
management including use of medication, identifying signs and symptoms of deterioration, problem-
solving, seeking support/health care professional input during usual care as well as rationale and 
expectation of participation in the study, perceived barriers and enablers to successful completion in 
the study. We anticipate that this short self-administered questionnaire will take approximately 30 
minutes to complete. The purpose of administrating this self-administered questionnaire is to use 
individual responses to act as an “aide memoire” at the follow up interviews. 
 
Analysis 
Data analysis will use the Framework Approach[10] which provides a systematic, auditable and 
rigorous analysis of qualitative data. It is also more deductive than other thematic analysis 
approaches and ensures that focused data is collected to answer the clear research objectives of the 
study. Experienced facilitators will independently code all data. Scrutiny of the framework matrix will 
be sought to see if there is agreement with the categories generated. In addition, a member of the 
steering group, not involved in data collection, will be asked to independently read through a sample 
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of the transcripts to generate a preliminary framework without seeing the original researchers’ list. 
In the case of disagreement, a solution will be sought to clarify the meaning of a code/theme 
developed until mutual consent is reached. The aim of this stage is to attempt to enhance the 
validity of the development of the conceptual framework and to guard against researcher bias.  A 
narrative summary will be developed from the findings which include comparison within case and 
across patient and carer’s perception and experience.  
Discontinuation/Withdrawal of Participants from the study 
Participants not complying with study requirements or failing to upload data or collect a sample will 
be re-trained. Significant non-adherence (e.g. non-collection of data and samples for a period of 
several weeks) may lead to withdrawal of the participant from the study by the study team. If 
participants/carers are not willing to continue data collection, they may decide to withdraw from the 
study, and will return all the equipment.  
 
Definition of End of Study 
The end of study is the date of the last sample and data upload of the last participant follow-up date, 
or the last qualitative interview, whichever comes last. 
 
ASSESSMENT OF SAFETY 
This is a non-interventional study and is therefore considered to be of no additional safety risk 
compared with usual clinical practice. All patients are expected to have a number of co-morbidities 
and on-going symptoms due to their illness. All study procedures in use are the usual standard of 
care for this population and are not novel. The test used to observe the variation in levels of Exotoxin 
A is a new test but one that is validated and in itself provides no risk of harm to the participants; it is 
not performed on the participant themselves but on their sputum, which they would ordinarily be 
producing daily, and it will not change any clinical treatment as the results will not be available to the 
participant or their clinical team. 
There is therefore no clear rationale for additional safety monitoring during the study period, or for 
the expedited reporting of any serious adverse events. However, as study procedures are being 
conducted more frequently by the patients in their homes (as part of their daily routine), there may 
be an increased frequency of expected side effects/adverse events for some patients.  The most 
likely AE during procedures is an increased risk of fainting for those participants who are susceptible 
to fainting during Spirometry (specifically daily peak flow, which requires blowing rapidly and 
forcefully into a spirometer). 
Therefore, the following risk-adapted safety monitoring procedures are to be followed during the 
study period. 
Participants will be asked to report any of the expected adverse events to the research team if they 
occur at a level which causes significant discomfort to the participant, so that the research team can 
provide any further training or adjustments to the way in which the measurements are taken, or 
reduce the frequency at which the participant is to take the measurement: 
 Dizziness / light-headedness 
 Fainting 
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The Chief investigator and study team will record and monitor any adverse events caused due to the 
increased frequency of the self-monitoring assessments. If there is any concern over these events or 
if they become unacceptable and in any circumstance cause the risk to benefit ratio to tip they 
should be expedited to the Sponsor and may subsequently reviewed by the Research Quality 
Committee (RQC). 
 
DATA HANDLING AND RECORD KEEPING 
Data Collection Forms 
The anonymous daily data generated by participants using the technology provided to them will be 
uploaded directly to the web servers of Aseptika Ltd via 3G built into the iPad tablets provided to the 
participants (see section Screening & Enrolment). The anonymised data collected at the hospital 
visits at baseline, 3 & 6 months will be recorded on study specific Case Report Forms (CRF’s). The 
data recorded on these forms will then be uploaded, by a member of the research team, onto the 
local study database held at Portsmouth Hospitals Trust. This database will be password protected 
and kept on a secure NHS server with restricted access on a computer with restricted access in a 
locked room.  
 
Data Management 
Each volunteer will be given an account within Activ8rlives on-line system.  Their names, NHS 
number, address or any other identifying information will not be entered.  Anonymity will be assured 
by giving each participant a unique study ID which will not be traceable to the participant. The 
unique study ID will be formed of two letters and two numbers (e.g. SE01 for the first participant 
recruited into the study, SE02 for the second participant recruited and so on). 
Aseptika Ltd.’s servers are located in the UK and have appropriate security measures.  Access to 
these data will be restricted to Director-level personnel within Aseptika Ltd and to the Research 
Nurse, for the purposes of technical support and to track progress of the study. Patients/carers, 
clinical staff and laboratory staff will have no access to these data. 
Data generated from sputum and urine analysis will be output to Excel spreadsheets and will be 
imported into the account for each volunteer to be correlated with other telemetry data. 
Other clinically relevant information (start of antimicrobial therapy, admission or other treatment 
which is associated with an endpoint will be entered into the Activ8rlives system. 
 
DATA ANALYSIS 
Description of Analysis Populations 
The study is a non-randomised cohort of a single group of patients. All subjects recruited into the 
study will be included in the data analysis. 
 
Analysis of Endpoints 
The first stage of the data analysis is to use data on the collected parameters (e.g. peak flow, pulse 
rate, oxygen saturation, activity data) to predict when an exacerbation is likely. Control charts will be 
used to determine the boundaries of ‘normal’ behaviour for each parameter. Separate control charts 
will be used for each participant, as what constitutes ‘normal’ behaviour will vary from participant to 
participant. When a parameter strays from ‘normal’ behaviour (e.g. exceeds 99% control limits) an 
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exacerbation will be predicted. 
To examine the association between predicted exacerbation and actual exacerbation, participant 
follow-up will be divided into periods of time (e.g. 7-10 days). A comparison of actual exacerbation 
when exacerbation has and has not been predicted will be made. To allow for the repeat 
measurements over time from the same participants, the analysis will be performed using multilevel 
logistic regression. 
 
Additionally, the sensitivity and positive predictive value of the predictions will also be calculated. 
Estimated values will be presented along with corresponding confidence intervals. 
Healthcare utilisation data will be presented descriptively, for example the frequency and type of 
healthcare contacts over the study period for different participant groups. 
 
Procedure for Dealing with Missing, Unused and Spurious Data 
The primary analysis will be restricted to collected data only, without any data imputation. The 
distributions of the parameters collected will be assessed, and implausible values may be excluded 
from the analysis. Any data exclusions will be justified both clinically and statistically.  
 
Procedures for Reporting any Deviation(s) from the Original Statistical Analysis  
Any deviations to the Statistical Analysis Plan will be carefully documented and justified. 
 
ETHICS 
The study will not be initiated before the protocol and all study relevant material such as informed 
consent forms, participant and GP information sheets have received approval / favourable opinion 
from the Research Ethics Committee (REC), and the respective National Health Service (NHS) 
Research& Development (R&D) department. Any changes to protocol or relevant study documents 
will be approved by the Sponsor. Should an amendment be made that requires REC approval, 
defined by REC as a substantial amendment, the changes will not be instituted until the amendment 
has been reviewed and received approval / favourable opinion from the REC and R&D departments. 
A protocol amendment intended to eliminate an apparent immediate hazard to participants may be 
implemented immediately providing that the REC are notified as soon as possible and an approval is 
requested. Minor amendments, defined by REC as non-substantial amendments, may be 
implemented immediately and the REC will be informed. 
 
Participant Confidentiality 
Study staff will ensure that the participants’ anonymity is maintained.  The participants will be 
identified only by initials and a participant’s ID number on the CRF and any electronic database.  All 
documents will be stored securely and only accessible by study staff and authorised personnel. The 
study will comply with the Data Protection Act which requires data to be anonymised as soon as it is 
practical to do so.   
 
Benefits and Burdens to Participants 
This study requires a high engagement and compliance rate from the study participants. 
The additional daily measurements, monitoring and downloading of the information onto the study's 
website for six months will be an additional time burden for the participants and may add 
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significantly to their already onerous treatment burden. Clear instruction, in-depth training and on-
going technical support for all of the study equipment, along with regular input from an experienced 
and committed research team will help to mitigate any burden. 
 
Participants will be required to store the various study equipment including a small study freezer, 
iPad mini and self-monitoring gadgets in their own homes which may be a burden for some 
participants, especially those living in smaller properties. Participants will be made aware of the 
equipment they will be provided with and information on how much space they will need to store 
the equipment, prior to consent. The capability to store the study equipment will be evaluated as 
part of a participant eligibility assessment prior to giving out participant information. 
 
A Research Nurse and Aseptika trainer will need to complete a one-off visit to participants’ homes to 
deliver, install and train the participant in the various study technology. To minimise the burden of 
this visit, participants will only ever be contacted by the research team, not the company and a visit 
time will be scheduled in advance, at a time that is convenient to the participant. 
 
On completion of the entire study, each participant and their carer will be shown the data and what 
has been learned from their participation in the study. 
 
Participant benefits include being compensated £1 a day for successfully completing the 
measurements and collecting samples, retaining the iPad mini and freezer, being provided with 3G 
connectivity for 6 months following completion of the study and retain ownership of the monitoring 
devices.  Participants will be encouraged to continue the self-monitoring process “unblinded” 
thereafter and will have full access to the data they generate. 
 
The study will be reviewed by the Research Quality Committee at regular intervals. 
 
PATIENT PUBLIC INVOLVEMENT (PPI) 
 The study design is similar to that of a previous study carried out with 15 cystic fibrosis patients in 
Cambridge. Adaptations of the content and methods of data collection and the final design of the 
questionnaire on the iPad will be informed by a group of PPI members convened for the purposes of 
this study. These members will be patients at PHT with similar respiratory conditions and will be 
invited to attend the group by their respective clinicians. PPI members have also given input on the 
study design and implementation issues, reviewed the Participant information sheet (PIS) and the 
informed consent form (ICF). Some key issues raised by the group are listed below, and these will be 
addressed in the preparation of study implementation: 
 How big is the freezer - concern over space at home 
 How often will samples be collected - concern about storage of samples and consumables 
and possible expenses to bring samples to the hospital, plus ensuring that any staff who 
collect samples from the house will have appropriate ID. 
 Ease of use of the Vacutainer urine collection system for participants with co-morbidities 
such as arthritis. 
 Recommended pre-printing of labels. 
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 Some apprehension about using an iPad. 
 Whether the participants who take part will get to know the results of the study. 
 What happens if participants wish to go on holiday 
 
RESULTS 
The SENSOR study is now in data analysis. It is anticipated results will be available by the end of 
2016. The use of technology by study participants was successful, with high upload figures and 
product reliability. 
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